



PRODUCT: **TPOXX®**

COMPANY: SIGA Technologies, Inc.

THERAPEUTIC AREA & INDICATION:

First drug with an indication for treatment of smallpox in humans in the event of its use as a bioweapon and public health emergency

ABOUT THE PRODUCT

TPOXX is indicated for the treatment of smallpox disease in adults and pediatric patients (>13kg). Tecovirimat targets and inhibits the exit of the variola virus that causes smallpox from infected cells, preventing its spread and infection of other cells. TPOXX was approved by the FDA using the “Animal Rule,” and is intended to treat humans with dosing of 600 mg twice daily for 14 days. TPOXX is among the first novel small molecule therapies delivered to the Strategic National Stockpile and would play a critical role in responding to a smallpox bioterror attack.